- Home
- CANF vs CNVS Comparison
CANF vs CNVS Comparison
Compare CANF & CNVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CANF
- CNVS
- Stock Information
- Founded
- CANF 1994
- CNVS 2000
- Country
- CANF Israel
- CNVS United States
- Employees
- CANF N/A
- CNVS N/A
- Industry
- CANF Biotechnology: Pharmaceutical Preparations
- CNVS Consumer Electronics/Video Chains
- Sector
- CANF Health Care
- CNVS Consumer Discretionary
- Exchange
- CANF Nasdaq
- CNVS Nasdaq
- Market Cap
- CANF 14.4M
- CNVS 22.8M
- IPO Year
- CANF N/A
- CNVS 2003
- Fundamental
- Price
- CANF $2.70
- CNVS $1.37
- Analyst Decision
- CANF Strong Buy
- CNVS Buy
- Analyst Count
- CANF 2
- CNVS 1
- Target Price
- CANF $14.00
- CNVS $9.00
- AVG Volume (30 Days)
- CANF 135.4K
- CNVS 216.2K
- Earning Date
- CANF 11-15-2024
- CNVS 11-12-2024
- Dividend Yield
- CANF N/A
- CNVS N/A
- EPS Growth
- CANF N/A
- CNVS N/A
- EPS
- CANF N/A
- CNVS N/A
- Revenue
- CANF $667,000.00
- CNVS $45,278,000.00
- Revenue This Year
- CANF $356.93
- CNVS $26.40
- Revenue Next Year
- CANF N/A
- CNVS N/A
- P/E Ratio
- CANF N/A
- CNVS N/A
- Revenue Growth
- CANF N/A
- CNVS N/A
- 52 Week Low
- CANF $1.81
- CNVS $0.72
- 52 Week High
- CANF $4.69
- CNVS $3.93
- Technical
- Relative Strength Index (RSI)
- CANF 65.91
- CNVS 75.10
- Support Level
- CANF $1.87
- CNVS $1.34
- Resistance Level
- CANF $2.55
- CNVS $1.67
- Average True Range (ATR)
- CANF 0.17
- CNVS 0.16
- MACD
- CANF 0.08
- CNVS 0.05
- Stochastic Oscillator
- CANF 91.43
- CNVS 66.31
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).
About CNVS Cineverse Corp.
Cineverse Corp is a main streaming technology and entertainment company. It operates portfolios of owned and operated streaming channels, all powered by its, proprietary technology platform. Cineverse features enthusiast brands for subscription video on demand (SVOD), advertising-based video on demand (AVOD), and free, ad-supported streaming television (FAST) channels. The company earns fees for the distribution of content in the home entertainment markets via several distribution channels, including digital, video-on-demand, and physical goods (e.g., DVDs and Blu-ray Discs) (Base Distribution).